GLSI
Neutral signalScored 2026-08-03 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
Greenwich LifeSciences, Inc.
- Nom
- Greenwich LifeSciences, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $222.8M
- Employés
- 13
- PDG
- Snehal S. Patel
- Site web
- https://greenwichlifesciences.com
- Marché
- AGENATOSCGTXHURAIMMXIRD
Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 7 300 titres (~97 003,00 $ US)
- Insiders
- Patel Snehal
- Total bought
-
$97,003
Avg buy (VWAP, 90d window) $13.51 vs last close —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-07-29
- Last synced
-
2026-10-19 22:07:50
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-07-29 | Patel Snehal | Buy · P | 700 | $13.10 | $9,170 | Form 4 |
| 2026-07-28 | Patel Snehal | Buy · P | 1,500 | $13.59 | $20,385 | Form 4 |
| 2026-07-27 | Patel Snehal | Buy · P | 1,500 | $13.62 | $20,430 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-08-03 Drivers: fundamentals. Moteurs : fondamentaux.
GLSI presents a meaningful event-driven catalyst — an insider cluster buy following back-to-back UK and European regulatory approvals for the FLAMINGO-01 trial — yielding an effective catalyst signal of ~52.5 after…
The first sentence of the analysis written for GLSI on 2026-08-03 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 1.06 · operating margin 0.0%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 1.061 | 1.285 | 23.741 | 51.228 | 70.629 | |
| Quick Ratio | 1.061 | 1.285 | 23.741 | 51.228 | 70.629 | |
| Solvency Ratio | -3.323 | -5.466 | -30.190 | -29.751 | -11.857 | |
| Cash Ratio | 1.061 | 1.285 | 23.741 | 51.228 | 70.629 | |
| Price To Earnings Ratio | -14.692 | -9.281 | -15.246 | -24.918 | -69.514 | |
| Price To Earnings Growth Ratio | -0.808 | -0.123 | -1.163 | -0.335 | -0.521 | |
| Forward Price To Earnings Growth Ratio | -0.808 | -0.123 | -1.163 | -0.335 | -0.521 | |
| Price To Earnings Diluted Ratio | -14.692 | -9.281 | -15.246 | -24.918 | -69.514 | |
| Price To Earnings Diluted Growth Ratio | -0.808 | -0.123 | -1.163 | -0.335 | -0.521 | |
| Price To Book Ratio | 805.086 | 160.851 | 20.172 | 14.855 | 11.737 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -28.685 | -20.113 | -20.863 | -31.660 | -73.384 | |
| Price To Operating Cash Flow Ratio | -28.685 | -20.113 | -20.863 | -31.660 | -73.384 | |
| Debt To Assets Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Debt To Equity Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 17.491 | 4.505 | 1.044 | 1.020 | 1.014 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -1.702 | -2.281 | -22.006 | -23.583 | -11.142 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Capital Expenditure Coverage Ratio | -3,304,484.333 | -2,422,181.000 | 0.000 | -2,066,675.667 | 0.000 | |
| Dividend Paid And Capex Coverage Ratio | -3,304,484.333 | -2,422,181.000 | 0.000 | -2,066,675.667 | 0.000 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -14.372 | -8.159 | -14.421 | -23.374 | -63.002 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 1.061 | ▼-0.224 | ▼-28.528 |
| Quick Ratio | 1.061 | ▼-0.224 | ▼-28.528 |
| Solvency Ratio | -3.323 | ▲2.143 | ▲12.794 |
| Cash Ratio | 1.061 | ▼-0.224 | ▼-28.528 |
| Price To Earnings Ratio | -14.692 | ▼-5.411 | ▲12.038 |
| Price To Earnings Growth Ratio | -0.808 | ▼-0.685 | ▼-0.218 |
| Forward Price To Earnings Growth Ratio | -0.808 | ▼-0.685 | ▼-0.218 |
| Price To Earnings Diluted Ratio | -14.692 | ▼-5.411 | ▲12.038 |
| Price To Earnings Diluted Growth Ratio | -0.808 | ▼-0.685 | ▼-0.218 |
| Price To Book Ratio | 805.087 | ▲644.235 | ▲602.546 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -28.685 | ▼-8.572 | ▲6.256 |
| Price To Operating Cash Flow Ratio | -28.685 | ▼-8.572 | ▲6.256 |
| Debt To Assets Ratio | 0.000 | 0.000 | 0.000 |
| Debt To Equity Ratio | 0.000 | 0.000 | 0.000 |
| Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 17.491 | ▲12.985 | ▲12.476 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -1.702 | ▲0.579 | ▲10.441 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 0.000 | 0.000 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Capital Expenditure Coverage Ratio | -3304484.333 | ▼-882303.333 | ▼-1745816.133 |
| Dividend Paid And Capex Coverage Ratio | -3304484.333 | ▼-882303.333 | ▼-1745816.133 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -14.372 | ▼-6.213 | ▲10.293 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $284.4M | $146.2M | $135.2M | $196.3M | $314.9M | |
| Enterprise value | $278.2M | $142.1M | $128.2M | $182.8M | $287.7M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -28.06x | -19.55x | -19.78x | -29.49x | -67.05x | |
| EV / Free cash flow | -28.06x | -19.55x | -19.78x | -29.49x | -67.05x | |
| EV / EBITDA | -14.37x | -8.16x | -14.42x | -23.37x | -63.00x | |
| Net debt / EBITDA | 0.32x | 0.23x | 0.79x | 1.72x | 5.96x | |
| Current ratio | 1.06x | 1.28x | 23.74x | 51.23x | 70.63x | |
| Income quality | 0.51x | 0.46x | 0.73x | 0.79x | 0.94x | |
| Graham net-net | $0 | $0 | $1 | $1 | $2 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $353K | $907K | $6.7M | $13.2M | $26.8M | |
| Invested capital | $353K | $909K | $6.7M | $13.2M | $26.8M | |
| Return on assets | -313.3% | -425.4% | -127.1% | -58.1% | -16.8% | |
| Operating ROA | -378.7% | -318.1% | -91.1% | -39.5% | -16.5% | |
| Return on tangible assets | -313.3% | -425.6% | -127.2% | -58.1% | -16.8% | |
| Return on equity | -5480.5% | -1916.5% | -132.7% | -59.2% | -17.0% | |
| Return on invested capital | -5505.9% | -1941.1% | -139.2% | -60.8% | -17.1% | |
| Return on capital employed | -5505.9% | -1941.1% | -139.2% | -60.8% | -17.1% | |
| Earnings yield | -6.8% | -11.9% | -6.6% | -4.0% | -1.5% | |
| Free cash flow yield | -3.5% | -5.0% | -4.8% | -3.2% | -1.4% | |
| Capex / Op. cash flow | -0.0% | -0.0% | 0.0% | -0.0% | 0.0% | |
| Capex / Depreciation | 0.2% | 0.1% | 0.0% | 0.1% | 0.0% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.1% | 0.1% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 1000106d | 283243d | 3585d | 22317d | 22317d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | -1000106d | -283243d | -3585d | -22317d | -22317d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-04 Greenwich LifeSciences (NASDAQ:GLSI) Stock Falls 2.1% – Time to Sell? Greenwich LifeSciences, Inc. (NASDAQ: GLSI - Get Free Report)''s stock price fell 2.1% during mid-day trading on Friday. The stock traded as low as $16.60 and last traded at $16.98. Approximately 175,415 shares traded hands during mid-day trading, an increase of 57% from the average session volume of 111,705 shares. The stock had previously closed at
- 2026-08-27 20 stocks likely to lose money even if the bull market continues Certain stocks are such poor bets that they are likely to lose ground even in bull markets.
- 2026-08-10 Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027 STAFFORD, Texas, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that its Board of Directors has extended the lock-up of the shares owned by the Company''s directors, officers, and existing pre-IPO investors to January 31, 2027 which is approximately 76 months from the date of the Company''s IPO. During this period, current officers, directors and certain shareholders will not be able to sell their shares of the Company''s common stock unless otherwise modified by the Board of Directors. After January 31, 2027, the quantity of these locked-up shares that can be sold daily and over various periods of time will be restricted under a leak-out plan unless otherwise modified by the Board of Directors.
- 2026-07-22 Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom STAFFORD, Texas, July 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the regulatory approval to expand FLAMINGO-01 into the United Kingdom.
- 2026-07-20 Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01 STAFFORD, Texas, July 20, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following clinical updates on FLAMINGO-01.